Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine Augmentation in Treatment-Resistant Depression
NCT00652171Phase 3Completed
- Sponsor
- IPSEMG
- Start
- Jan 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Lamotrigine with Placebo (2 arms). Primary endpoint: Montgomery and Asberg Scale for Depression at 8 weeks. Started Jan 2004; status: completed.
02
Drugs
lamotrigine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00652171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00652171.